Cardiovascular leaders who are making a real difference
Dean Y. Li, cardiologist and president of Merck Research Laboratories (MRL), discusses the state of fighting cardiovascular disease and our efforts that will push us to new heights to help patients improve their quality of cardiovascular and respiratory health.
“We've created a broad, promising pipeline to build on our legacy, and are deploying our unique expertise to advance innovations to people who need them.”
Making a heartfelt difference
Making a heartfelt difference
Join our efforts toward cardiovascular and respiratory success.
Our R&D efforts
We’re determined to build upon our fundamental research strengths to deliver innovation to patients and physicians worldwide, expand our legacy of invention every day, and provide biomedical leadership in pharmaceutical R&D to address unmet needs and the best external science. Our therapeutic areas of focus are defined by our strongest scientific discoveries and our dedication to advance the most promising product opportunities.
Our commercial efforts
Our commercial organization is driven by the impact they can make in offering hope to patients. Our teams in sales, marketing, market access, and business development work tirelessly to convert innovative science into deliverable offerings that support patients, payers, and physician’s needs. We take a customer-centric approach leveraging emerging digital technologies and data analysis to better understand our patients needs and to improve patients’ access to our medicines.
How we’re making the most difference
Our biggest, most effective differentiator: the strong, cohesive bond between our R&D and commercial teams that allows us to continue to fight the cardiovascular disease epidemic with everything we’ve got. Join a collaborative and innovative team of Cardiovascular & Respiratory Research & Development (MRL) and Human Health (HH) professionals in truly transformational medical science.
Voices of cardiovascular & respiratory success
“
What I have enjoyed most since transitioning from academic medicine to Merck is working together in cross functional teams to collaborate on the strategy and execution of clinical development plans for exciting new drugs in the cardiovascular pipeline.
G. Brandon Atkins
Dist. Scientist, Clinical Research, GCD Cardiovascular & Respiratory
“
Merck aims to improve the lives of patients with cardiovascular and respiratory diseases through meaningful investment in creating leaders in cardiovascular and respiratory drug development.
Paul Reyfman
Principal Scientist, Clinical Research, GCD Cardiovascular & Respiratory
“
I’m humbled to be part of a team inspired and driven by the singular purpose to uncover, develop and deliver breakthroughs for patients as quickly and safely as possible.
Adam Castaño
MD, MS, Senior Medical Director, Global Clinical Development, Cardiovascular Disease
“
I joined our team to impact patient care at a larger scale, but I still carry my patients' stories with me.
Joerg Koglin
VP, Therapeutic Area Head, Global Clinical Development, Cardiovascular
